Retatrutide vs Mounjaro vs Ozempic: A Research Comparison of Triple, Dual, and Single Agonists

Few topics generate more confusion in the metabolic research space than the relationship between retatrutide, Mounjaro, and Ozempic. The names get used interchangeably in forum threads and search queries, yet they describe very different things. Two are finished, FDA-approved prescription medications. One is an investigational compound studied in laboratory and clinical-trial settings. This guide untangles the difference and compares the underlying science, the triple, dual, and single receptor agonist mechanisms, in strictly research terms.

A clear note before going further. The information below is for educational and laboratory-research context only. It does not describe how to dose, administer, or self-treat anything, and the research compounds discussed are intended for in-vitro and laboratory study, not human consumption.

Key Takeaways

• Mounjaro is tirzepatide, an FDA-approved prescription drug, and Ozempic and Wegovy are semaglutide, also FDA-approved prescription drugs. Retatrutide (LY3437943) is an investigational compound studied in research and clinical-trial settings, not an approved medicine.
• The core scientific difference is receptor coverage: semaglutide is a single agonist (GLP-1), tirzepatide is a dual agonist (GLP-1 and GIP), and retatrutide is a triple agonist (GLP-1, GIP, and glucagon).
• In published phase 2 research, retatrutide's highest dose produced roughly 24.2 percent mean body-weight reduction in study models over 48 weeks, alongside up to an 82 percent reduction in liver fat.
• Research peptides such as retatrutide are sold and used for laboratory study only. They are not substitutes for prescription medicines and are not positioned as Mounjaro, Ozempic, or Wegovy.
• Retatrutide has a CAS number of 2381089-83-2, a molecular weight near 4731.41, and an albumin-binding design that gives it a half-life of approximately six days in research pharmacokinetics.
• For research-grade material, third-party HPLC testing, a published certificate of analysis (COA), and verified 99 percent-plus purity are the only meaningful trust signals.

Drugs Versus Research Compounds: The Distinction That Matters Most

The single most important point in any "retatrutide vs Mounjaro" or "retatrutide vs Ozempic" comparison is regulatory status, because it changes what each substance legally is.

Mounjaro is the brand name for tirzepatide, approved by the FDA for type 2 diabetes, with the same molecule sold as Zepbound for chronic weight management. Ozempic is the brand name for semaglutide, approved for type 2 diabetes, with the same molecule sold as Wegovy for weight management. These are finished pharmaceutical products, manufactured under prescription-drug controls and dispensed by licensed providers.

Retatrutide is none of those. It is an investigational triple-hormone-receptor agonist still moving through clinical development, with phase 3 TRIUMPH trials ongoing as of 2026. When you see retatrutide offered as a research peptide, it is supplied for laboratory and in-vitro study, not as a drug and not as a generic version of any approved medicine. Researchers investigating incretin biology purchase it the way they purchase any reference compound: to run experiments, not to treat anyone. Lyze Labs supplies retatrutide on exactly that basis. The same framing applies to our tirzepatide dual agonist research guide and semaglutide research guide, where each compound is treated as a laboratory reference standard.

Single, Dual, Triple: How the Mechanisms Differ

The most useful way to compare these molecules is by the receptors they engage. Each added receptor target broadens the metabolic pathways the compound can influence in research models.

Semaglutide (single agonist). Semaglutide activates the GLP-1 receptor only. In study models, GLP-1 receptor activity is associated with slowed gastric emptying, enhanced glucose-dependent insulin secretion, suppressed glucagon release, and reduced food-seeking signaling. It is the most established of the three, and semaglutide carries the strongest published cardiovascular outcome data, with the SELECT trial showing a roughly 20 percent reduction in major adverse cardiovascular events in its study population.

Tirzepatide (dual agonist). Tirzepatide adds GIP receptor activity on top of GLP-1. The GIP arm appears to modulate insulin sensitivity and adipose-tissue handling in ways that, in head-to-head research, drive larger effects than GLP-1 alone. In the 2025 SURMOUNT-5 study, tirzepatide produced about 20.2 percent body-weight reduction versus 13.7 percent for semaglutide in the same trial design.

Retatrutide (triple agonist). Retatrutide engages all three: GLP-1, GIP, and glucagon (GCGR). The glucagon receptor is the differentiator. While GLP-1 and GIP activity center on appetite and insulin pathways, glucagon receptor agonism is linked in research to increased energy expenditure and hepatic fatty-acid oxidation. The glucagon receptor is densely expressed in the liver, which is why phase 2 imaging data showed such pronounced reductions in hepatic fat. For a deeper mechanistic breakdown, see the retatrutide triple agonist research guide product page and our standalone retatrutide triple agonist research guide.

Side-by-Side Research Comparison

The table below summarizes the published research and regulatory profile of all three compounds. All efficacy figures come from clinical-trial and research-model data, not from any individual protocol.

What the Glucagon Receptor Adds in Research Models

Researchers studying retatrutide are most interested in the glucagon arm because it represents a mechanistic shift. In preclinical work, retatrutide induced greater body-weight reduction in obese animal models than tirzepatide, attributed to increased energy expenditure through GCGR activation rather than appetite suppression alone.

That same glucagon activity drives the liver findings. A randomized phase 2a study in metabolic-dysfunction-associated steatotic liver disease (MASLD) reported dramatic hepatic-fat reductions, with the headline figure reaching roughly 82 percent in higher-dose research arms. Because glucagon stimulates hepatic fatty-acid oxidation and dampens lipogenesis, the liver becomes a primary site of measurable effect, which is why hepatic-fat imaging is a recurring endpoint in retatrutide research.

The phase 3 TRIUMPH-1 readout has since reinforced the bariatric-level magnitude of effect seen in phase 2, while the TRIUMPH-Outcomes trial is specifically designed to test whether the triple-agonist profile changes cardiovascular results. Until those datasets fully mature, retatrutide remains an investigational compound, which is exactly why it sits in the research category rather than the pharmacy.

Why "Tirzepatide vs Mounjaro" and "Tirzepatide vs Ozempic" Are Slightly Wrong Questions

A large share of search traffic asks "tirzepatide vs Mounjaro" or "tirzepatide vs Ozempic." The first comparison is essentially a category question rather than a molecular one: tirzepatide is the active ingredient in Mounjaro, so comparing them is comparing a molecule to its own brand-name product. The meaningful distinction is between tirzepatide-the-compound (studied as a research peptide) and Mounjaro-the-finished-drug (a prescription product).

"Tirzepatide vs Ozempic" is a real molecular comparison, because Ozempic is semaglutide. That is a dual-agonist versus single-agonist question, and the research data consistently shows the dual agonist producing larger effects in matched study designs. If you are mapping the full landscape, our retatrutide vs tirzepatide vs semaglutide deep dive lays out all three in one place.

Sourcing Research-Grade Retatrutide

Because retatrutide is investigational, quality control is entirely on the supplier, and the only signals that matter are verifiable. For any research peptide, the checklist is the same: third-party HPLC analysis, a published certificate of analysis tied to the specific batch, and confirmed 99 percent-plus purity. If a vendor cannot produce a batch-matched COA, the material should be treated as unverified. Our how to verify research peptide purity COA guide walks through reading an HPLC report line by line.

Lyze Labs publishes a COA for every batch, with all material third-party HPLC tested to 99 percent-plus purity, and is trusted by more than 12,000 researchers across 50 or more countries at a 4.8 out of 5 rating. Ordering is simplest over WhatsApp, the fastest channel, and we also accept Visa, Mastercard, UPI, PayPal, CashApp, bank and wire transfer, and crypto including BTC, USDT, and ETH. Shipping is free, discreet, and worldwide, typically arriving in 7 to 14 days. With GLP-1 and triple-agonist research demand surging, batch availability moves quickly, so securing current batch pricing early is worth doing.

Frequently Asked Questions

Is retatrutide the same as Mounjaro or Ozempic?

No. Mounjaro is the FDA-approved drug tirzepatide and Ozempic is the FDA-approved drug semaglutide. Retatrutide (LY3437943) is a separate investigational triple-agonist compound studied in laboratory and clinical-trial settings. It is supplied as a research peptide for laboratory study only and is not a substitute for any approved medicine.

What is the difference between retatrutide vs Mounjaro at the mechanism level?

Mounjaro contains tirzepatide, a dual agonist that activates the GLP-1 and GIP receptors. Retatrutide is a triple agonist that adds a third target, the glucagon receptor. In research models, that glucagon activity is associated with increased energy expenditure and pronounced reductions in liver fat, which is the main mechanistic distinction between the two.

How does retatrutide vs Ozempic compare in research data?

Ozempic is semaglutide, a single GLP-1 receptor agonist. Retatrutide engages three receptors. In published phase 2 research, retatrutide's highest dose produced roughly 24.2 percent mean weight reduction in study models, compared with the single-digit-to-mid-teens range seen with semaglutide in matched trials. These are laboratory and clinical-trial figures, not dosing recommendations.

Is tirzepatide vs Mounjaro even a valid comparison?

Not really, because tirzepatide is the active ingredient inside Mounjaro. The useful distinction is between tirzepatide studied as a research peptide and Mounjaro as a finished, FDA-approved prescription drug. The molecule is identical; the regulatory status and intended use are completely different.

Why is retatrutide sold as a research peptide instead of a drug?

Retatrutide has not completed the full FDA approval process and remains in phase 3 trials as of 2026. Until approval, it cannot be marketed or used as a medicine. It is therefore supplied strictly for in-vitro and laboratory research, where scientists study its triple-receptor mechanism, pharmacokinetics, and metabolic effects.

How do I verify the quality of research-grade retatrutide?

Look for three things: a batch-specific certificate of analysis, third-party HPLC testing, and confirmed 99 percent-plus purity. A supplier that publishes a COA tied to the exact batch you receive is giving you verifiable proof of identity and purity. Material without batch-matched documentation should be treated as unverified.

Order Research-Grade Retatrutide

For laboratory research into triple-agonist mechanisms, buy retatrutide with a published, batch-matched COA, third-party HPLC verification, and 99 percent-plus purity. Message us on WhatsApp for the fastest order processing, choose from card, UPI, PayPal, CashApp, bank transfer, or crypto, and get free discreet worldwide shipping in 7 to 14 days. Current batch stock is limited as demand climbs, so secure today's batch pricing while it lasts.